Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

AZD8186 First Time In Patient Ascending Dose Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01884285
Recruitment Status : Active, not recruiting
First Posted : June 24, 2013
Last Update Posted : June 20, 2019
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
This is a phase I, open-label, multicentre study of AZD8186 administered orally in patients with advanced castrate-resistant prostate cancer (CRPC), squamous non-small cell lung cancer (sqNSCLC), triple negative breast cancer (TNBC) and known PTEN-deficient/mutated or PIK3CB mutated/amplified advanced solid malignancies as monotherapy and in combination with abiraterone acetate or AZD2014.

Condition or disease Intervention/treatment Phase
Advanced Castrate-resistant Prostate Cancer CRPC Squamous Non-Small Cell Lung Cancer sqNSCLC Triple Negative Breast Cancer TNBC Drug: Part A: AZD8186 monotherapy Drug: Part B: AZD8186 monotherapy Drug: Part C1: Abiraterone acetate combination with AZD8186 Drug: Part D1: AZD2014 combination with AZD8186 Drug: Part D2 AZD2014 combination with AZD8186 Drug: Part C2: Abiraterone acetate combination with AZD8186 Phase 1

Detailed Description:

This is a phase I, open-label, multicentre study of AZD8186 administered orally in patients with advanced castrate-resistant prostate cancer (CRPC), squamous non-small cell lung cancer (sqNSCLC), triple negative breast cancer (TNBC) and known PTEN-deficient/mutated or PIK3CB mutated/amplified advanced solid malignancies. The study design allows an escalation of dose with intensive safety monitoring to ensure the safety of the patients.

There are 4 parts to this study: Part A, monotherapy dose escalation, Part B, monotherapy expansion cohort(s) in PTEN deficient patients at the monotherapy intended therapeutic dose(s) and schedule(s), Part C, AZD8186 added to abiraterone accetate (with prednisone) treatment - dose/ schedule finding followed by expansion phase in PTEN-deficient/mutated or PIK3CB mutated mCRPC and Part D, AZD8186 in combination with AZD2014 (a novel dual mTORC1/2 inibitor) dose/schedule finding followed by expansion phase in PTEN-deficient/mutated or PIK3CB mutated TNBC.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 150 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of AZD8186 in Patients With Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient/Mutated or PIK3CB Mutated/ Amplified Advanced Solid Malignancies as Monotherapy and in Combination With Abiraterone Acetate or AZD2014
Actual Study Start Date : July 9, 2013
Actual Primary Completion Date : March 29, 2019
Estimated Study Completion Date : September 30, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Part A: AZD8186 monotherapy
Patients will receive a single dose on Day 1 followed by ongoing multiple dosing. The initial schedule will use intermittent dosing of AZD8186.
Drug: Part A: AZD8186 monotherapy
The initial schedule will use intermittent dosing of AZD8186. Dose, frequency and schedule in subsequent cohorts may be modified in response to safety, tolerability, pharmacokinetic and preclinical data.

Experimental: Part C2: AZD8186/abiraterone
Patients will receive a week of abiraterone acetate with prednisone followed by combination dosing with AZD8186.
Drug: Part C2: Abiraterone acetate combination with AZD8186
Dose expansion of AZD8186 at dose determined in Part C1 added to approved dose of abiraterone acetate (with prednisone)

Experimental: Part D1: AZD8186 and AZD2014
Combination dosing with AZD8186 and AZD2014 both given on an intermittent schedule at escalating dose levels of each IMP for combination dose finding
Drug: Part D1: AZD2014 combination with AZD8186
Dose & schedule finding of AZD8186 in combination with AZD2014

Experimental: Part B: AZD8186 monotherapy
Part B - multiple dosing of intermittent dose schedule
Drug: Part B: AZD8186 monotherapy
Part B will be at a dose(s) and schedule(s) at or below from Part A

Experimental: Part D2: AZD8186/ AZD2014
Expanded cohort of patients will be treated at a tolerated combination dose level established in Part D1
Drug: Part D2 AZD2014 combination with AZD8186
Combination AZD8186/ AZD2014 dose expansion at dose determined in Part D1

Experimental: Part C1: AZD8186 & abiraterone
Patients will receive a week of abiraterone acetate with prednisone followed by combination dosing with AZD8186 at escalating doses of AZD8186 for the purpose of dose finding
Drug: Part C1: Abiraterone acetate combination with AZD8186
Dose and schedule finding of AZD8186 added to approved labelled dose of abiraterone acetate (with prednisone).




Primary Outcome Measures :
  1. Safety and tolerability [ Time Frame: Routine safety assessments, throughout the period that patients receive AZD8186 up to 30 days following discont of last dose of study treatment. ]
    Assess safety and tolerability of AZD8186 when given as monotherapy or in combination with abiraterone acetate (with prednisone) or with AZD2014 by measuring AEs, SAE (incl death), safety measures incl ECG, physical exam, pulse, blood pressure, weight, lab variables


Secondary Outcome Measures :
  1. Part A: The number of evaluable patients with dose limiting toxicities (DLTs). [ Time Frame: DLTs assessed during the first 21 days of multiple dosing. ]
    Measure the number of evaluable patients with reported dose limiting toxicities (DLTs) at escalating dose levels and different intermittent and continuous dose schedules of AZD8186 monotherapy

  2. Part A, B, C + D: Antitumor activity of AZD8186 monotherapy or in combination [ Time Frame: Every 12 weeks (non prostate patients) or every 6 weeks (prostate patients) from baseline up to disease progression or withdrawal of consent ]
    Evaluation of tumour response using RECIST 1.1 or Prostate Cancer Clinical Trials Working Group (PCWG2) criteria for those patients with prostate cancer

  3. Part A, B, C and D: Anti-tumour activity of AZD8186 monotherapy or in combination [ Time Frame: PSA at Screening, Days 1, 8 & 15 then every 28 days, discontinuation of treatment (on average after 4 months), 30-day follow-up: CTC enumeration Days 1, 56 & 84, then every 12 weeks, at discontinuation (on average after 4 months). ]
    Measurement of changes in circulating prostate-specific antigen (PSA) and circulating tumour cells (CTC) enumeration in pts with prostate cancer.

  4. Part A + B: Plasma concentrations of AZD8186 and pharmacokinetic parameters (Cmax, tmax, AUC, terminal rate constant, clearance, half life, volume of distribution and mean resistance time) [ Time Frame: Prior to first dose and during first 28 days of treatment ]
    Blood samples will be collected at multiple timepoints on 2 intense PK collection days, with sparse sampling on additional days.

  5. Part A + B: 4 beta-hydroxy cholesterol concentration in blood samples. [ Time Frame: Blood samples will be collected from all patients for 4 beta-hydroxy cholesterol concentration measurements pre-dose day 1 and pre-morning dose day 22 in both Part A and B. ]
    Understanding of the CYP3A4 induction potential of AZD8186

  6. Part B: Obtaining a preliminary assessment of the antitumour activity of AZD8186 as monotherapy [ Time Frame: Paired tumour biopsies will be collected; one prior to treatment and the other during treatment (after at least 3 consecutive days of dosing 2-4 hours post-dose during 2nd week of trreatment) ]
    Evaluation of proof of mechanism biomarkers in PTEN-deficient TNBC or mCRPC tumour tissue

  7. Part B: Obtaining a preliminary assessment of AZD8186 drug effect in the tumour [ Time Frame: Paired tumour biopsies will be collected; one prior to treatment and the other during treatment (after at leat 3 consecutive days of dosing 2-4 hours post-dose in the second week of treatment) ]
    Evaluation of pharmacodynamics biomarker changes in tumour tissue

  8. Part A: Urine concentrations of AZD8186 and pharmacokinetic parameters (Cmax, tmax, AUC, terminal rate constant, clearance, half life, volume of distribution and mean residence time) [ Time Frame: Urine samples will collected at multiple time points: Day 1 (predose, 15min post dose, 30min post dose); Last dosing day during week 3 (predose and 15min post dose) ]
    Evaluation of the pharmacokinetics of AZD8186

  9. Part C: safety and tolerability assessed by dose limiting toxicity of AZD8186 with abiraterone acetate (and prednisone) [ Time Frame: DLTs assessed during the first 21 days of multiple dosing ]
    Dose limiting toxicity of AZD8186 when given at different doses and schedules in combination with abiraterone (with prednisone)

  10. Part C: pharmacokinetics of and exposure to AZD8186, its major metabolite M1, and abiraterone [ Time Frame: Blood samples will be collected at multiple timepoints on 2 intense PK collection days between screening and the end of the first 28 days of combination treatment. ]
    Assess the impact of co-administration on pharmacokinetics of and exposure to AZD8186, its major metabolite M1, and abiraterone

  11. Part C: steady state exposure to abiraterone [ Time Frame: Blood samples will be collected at multiple timepoints on 2 intense PK collection days between screening and the end of the first 28 days of combination treatment. ]
    Measure the steady state exposure to abiraterone in the absence and presence of steady state AZD8186

  12. Part C: steady state exposure of AZD8186 in combination with abiraterone acetate [ Time Frame: Blood samples will be collected at multiple timepoints on 2 intense PK collection days between screening and the end of the first 28 days of combination treatment. ]
    Measure the steady state exposure of AZD8186 in combination with abiraterone acetate and compare to previous steady state exposures when administered as a monotherapy

  13. Part D: Measure the dose limiting toxicity of AZD8186 in combination with AZD2014. [ Time Frame: DLTs assessed during the first 21 days of multiple dosing ]
    Safety and tolerability of the combination of AZD8186 and AZD2014

  14. Part D: Single dose and multiple dose pharmacokinetics of and assess exposure to AZD8186, its major metabolite M1, and AZD2014 when co-administered [ Time Frame: Blood samples will be collected at multiple timepoints on intense PK collection days for AZD8186 and AZD2014 monotherapy run-in, cycle 0 (single dose), day 9 (multiple dose) ]
    Measure the pharmacokinetics of and exposure to AZD8186, its major metabolite M1, and AZD2014 when co-administered

  15. Part D: Measure the exposure to AZD2014 following the last weekly dose of AZD2014 in the absence and presence of multiple dose AZD8186. [ Time Frame: Blood samples will be collected at multiple timepoints on intense PK collection days for AZD8186 and AZD2014 monotherapy run-in, cycle 0 (single dose), Day 9 of treatment (multiple dose) ]
    Assessment of exposure to AZD2014 in absence and presence of multiple dose AZD8186

  16. Part D: Measure the exposure on the 4th administred dose of AZD8186 in the absence and presence of multiple dose AZD2014 [ Time Frame: Blood samples will be collected at multiple timepoints on intense PK collection days for AZD8186 and AZD2014 monotherapy run-in, cycle 0 (single dose), day 9 (multiple dose) ]
    Assessment of exposure of AZD8186 in absence and presence of multiple dose AZD2014



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of signed and dated, written informed consent prior to any study specific procedures
  • Male or female, aged 18 years and older
  • Histologically or cytologically proven diagnosis of prostate cancer, sqNSCLC, TNBC, or known PTEN-deficient solid malignancy, and is refractory to standard therapies.
  • Females should be using adequate contraceptive measures, not be breast feeding and must have negative pregnancy test prior to start of dosing if of child-bearing potential
  • WHO/ECOG performance status 0 to 1 with no deterioration over the previous 2 weeks and min life expectancy of 12 weeks
  • Tumours that are known to have genomic alterations in PTEN or PIK3CB by local test results may also be eligible.

Part B - Tumour amenable to taking of paired biopsies in opinion of the investigator.Patients with TNBC or mCRPC: PTEN-deficient tumours

Parts A,B or D1(mCRPC)

  • PSA at screening must be ≥2 µg/L.
  • Preceding line of treatment included response to anti-androgen, progression documented after withdrawal of the anti-androgen.
  • Serum testosterone concentration ≤50 ng/dL sustained by medical or surgical castration

Parts A,B or D (TNBC)

- Oestrogen receptor, progesterone receptor and HER2 negative advanced adenocarcinoma of breast.

Parts A, B or D1 (solid malignancies) - Consented provision of formalin fixed paraffin embedded blocks/ slides from most recent tissue sample.

Part C (all patients):

  • May have received treatment with abiraterone acetate, enzalutamide and/or one prior chemotherapy (docetaxel)
  • Serum testosterone concentration ≤50 ng/dL sustained by medical or surgical castration.
  • Early or confirmed evidence of progressive disease.
  • Last PSA value should have increase of ≥ 25% of the first PSA value and an absolute increase of ≥2 ng/mL over the first PSA value
  • Serum potassium > 3.5 mmol/L

Parts C2 and D2

- Prospectively determined eligible PTEN alteration determined by next generation sequencing, protein deficient determined by IHC or PIK3CB mutation/amplification.

Part D2

- Measurable disease (at least 1 lesion ≥10 mm longest diameter or for lymph nodes short axis ≥15 mm) by CT/MRI

Exclusion Criteria

  • Treatment before study with

    1. Nitrosourea or mitomycin C within 6 weeks
    2. Investigational agents from previous clinical study within 4 weeks
    3. Chemotherapy, immunotherapy or anticancer agents within 4 weeks
    4. hormonal therapy
  • Treatment before study with

    1. Strong inhibitors and strong or moderate inducers of CYP3A4
    2. Radiotherapy with a wide field of radiation within 4 weeks,
  • With the exception of alopecia or toxicities related to the use of gonadotropin-releasing hormone agonists any unresolved toxicities from prior therapy greater than CTCAE grade 1 at time of study treatment
  • Spinal cord compression or brain metastases unless asymptomatic treated and stable and not requiring steroids
  • Evidence of severe or uncontrolled systemic diseases including active liver disease (other than malignancy), active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).

Exclusion crtieria Part C

  • Pre-existing Grade 2 or higher chronic diarrhoea
  • Major bowel surgery which in the opinion of the Investigator should exclude the patient
  • Use of antibiotics to treat chronic infections within 28 days prior to first dose
  • Sensitive or narrow therapeutic range substrates of CYP2D6
  • Severe or moderate hepatic impairment
  • Persistent uncontrolled hypertension (systolic >160 mmHg/ diastolic >100 mmHg

Exclusion Criteria Part D

  • Exposure to potent or moderate inhibitors or inducers of CYP3A4/5 and CYP2C8 if taken within the stated washout periods before the first dose
  • Exposure to sensitive or narrow therapeutic range substrates of the drug metabolising enzymes CYP2C8, CYP2C9, CYP2C19 or the drug transporters Pgp, BCRP, OATP1B1, OATP1B3, OCT1 and OCT2 within the appropriate wash-out period before the first dose of study treatment.
  • Haemopoietic growth factors within 2 weeks prior to receiving study drug.
  • Patients who have experienced any of the following procedures or conditions currently or in the preceding 12 months: coronary artery bypass graft, vascular stent, myocardial infarction, angina pectoris, congestive heart failure New York Heart Association Grade ≥2, supraventricular arrhythmias including atrial fibrillation, which are uncontrolled, haemorrhagic or thrombotic stroke, including transient ischaemic attacks or any other central nervous system bleeding.
  • Abnormal ECHO or MUGA at baseline <55%.
  • Patients with Diabetes Type I or uncontrolled Type II as judged by the Investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01884285


Locations
Layout table for location information
United States, Massachusetts
Research Site
Boston, Massachusetts, United States, 02215
United States, Michigan
Research Site
Detroit, Michigan, United States, 48201
United States, New York
Research Site
New York, New York, United States, 10065
United States, Washington
Research Site
Seattle, Washington, United States, 98109
United States, Wisconsin
Research Site
Madison, Wisconsin, United States, 53792-5666
Canada, Ontario
Research Site
Toronto, Ontario, Canada, M5G 2M9
Spain
Research Site
Barcelona, Spain, 08035
Research Site
Barcelona, Spain, 8036
Research Site
Pozuelo de Alarcon, Spain, 28223
United Kingdom
Research Site
Cambridge, United Kingdom, CB2 0QQ
Research Site
London, United Kingdom, WC1E 6BT
Research Site
Manchester, United Kingdom, M20 4BX
Research Site
Sutton, United Kingdom, SM1 2DL
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Study Director: Michele Mochetta, MD AstraZeneca
Principal Investigator: Lillian Siu, MD Princess Margaret Hospital, Canada

Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01884285     History of Changes
Other Study ID Numbers: D4620C00001
First Posted: June 24, 2013    Key Record Dates
Last Update Posted: June 20, 2019
Last Verified: June 2019

Keywords provided by AstraZeneca:
Advanced Castrate-resistant Prostate Cancer(CRPC)
Squamous Non-Small Cell Lung Cancer(sqNSCLC)
Triple Negative Breast Cancer(TNBC)
PTEN-deficient/mutated Advanced Solid Malignancies
PIK3CB mutated/amplified advanced solid malignancies

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Lung Neoplasms
Prostatic Neoplasms
Carcinoma, Non-Small-Cell Lung
Triple Negative Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Prednisone
Abiraterone Acetate
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Steroid Synthesis Inhibitors
Enzyme Inhibitors